Drug Interactions in Psoriasis: The Pros and Cons of Combining Topical Psoriasis Therapies

Goekerman WH . Treatment of psoriasis. Northwest Med 1925; 24:229–231

Gerritson MJ Rulo HF Van Vlijmen-Willems I . Topical treatment of psoriatic plaques with 1,25 dihydroxyvitamin D3: A cell biological study. Br J Dermatol 1993; 128:666–673

Keichrath J Perez A Muller SM . Topical calcitriol (1,25 dihydroxyvitamin D₃) treatment of psoriasis: An immunohistological evaluation. Acta Dermatol 1997; 77:268–272

Fogh K Kragballe K . Vitamin D₃ analogues. Clin Dermatol 1997; 15:705–713

Lamba S Lebwohl M . Combination therapy with vitamin D analogues. Br J Dermatol 2001; 144:27–32

Lebwohl M Abel E Zanolli M . Topical therapy for psoriasis. Int J Dermatol 1995; 34:673–684

Bruce S Epinette WW Funicella T . Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994; 31:755–759

Lebwohl M Siskin SB Epinette W . A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1998; 39:447–450

Kowalzik L . Clinical experience with topical calcitriol (1,25 dihydroxyvitamin D₃) in psoriasis. Br J Dermatol 2001; 144:21–25

Dwyer C Chapman RS . Calcipotriol and hypercalcemia. Lancet 1991; 338:764–765

Katz HI Hien NT Prawer SE . Betamethasone dipropionate in optimized vehicle: Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987; 123:1308–1311

Lebwohl M Yoles A Lombardi K . Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement. J Am Acad Dermatol 1998; 39:447–450

Kragballe K . Vitamin D₃ analogues. Dermatol Clin 1995; 13: 835–839

Patel B Siskin S Krazmien R . Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998; 38:1010–1011

Esgleyes-Ribot T Chandraratna RA Lew-Kaya DA . Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1998; 30:581–590

Chandraratna RAS . Tazarotene: First of a new generation of receptor-selective retinoids. Br J Dermatol 1996; 135:18–25

Gollnick H Menter A . Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999; 140:18–23

Liem WH McCullough JL Weinstein GD . Is topical therapy effective for psoriasis? Results of a survey of U.S. dermatologists [abstract]. Clin Res 1992; 40:495A

Poulin YP . Tazarotene 0.1% gel in combination with mometasone furcate cream in plaque psoriasis: A photographic tracking study. Cutis 1999; 63:41–48

Lebwohl M Ast E Callen JP . Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 38:705–711

Lebwohl M Poulin Y . Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol 1998; 39:S139–S143

Lebwohl M . Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000; 43:S43–S46

Lombardi K Tan M-H Lebwohl M . Duration of remission of psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: Comparison of maintenance treatment. Poster presented at the 57 Annual Meeting of the American Academy of Dermatology, July 28–August 1, 1999, New York, NY.

Kaidbey K Kooper SC Sefton J , A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Poster presented at the 58th Annual Meeting of the American Academy of Dermatology, March 10–15, 2000, San Francisco, CA.

Guendier L . Tazarotene combination treatments in psoriasis. J Am Acad Dermatol 2000; 43:S36–S42

Hecker D Worsley J Yueh G . In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol 2000; 42:1008–1011

Obermayer ME Becker SW . A study of crude coal tar and allied substances: A preliminary report. Arch Dermatol Syphil 1935; 31:796–810

Vahrman M . Origin of some primary coal tar components. Nature 1961; 189:136–137

Lowe NJ Breeding J . Anthralin, effects of different concentrations on epidermal DNA synthesis rates in mice and clinical response in psoriasis. Arch Dermatol 1981; 117:698–700

Walter JF Stoughton RB DeQuoy PR . Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin. Br J Dermatol 1978; 99:89–96

Silverman A Menter A Hairston JL . Tars and anthralins. Dermatol Clin 1995; 13:817–833

Harris DR . Old wine in new bottles. Cutis 1998; 62:201–203

Buschmann M Runne U . The anthralin (dithranol) erythema; influence of concentration contact time, oxidation products, salicylic acid, and corticosteroids: Clinical and reflection photometric examination. Acta Dermatol Venereol (Stockh) 1984; 63:152–155

Lawrence CM Shuster S . Topical indomethacin does not inhibit anthralin irritancy. Br J Dermatol 1984; 111:704–705

Marley WM Hernandez AD Josephs JA . The effectiveness of low strength anthralin in psoriasis. A comparison study. Arch Dermatol 1982; 118:906–908

Lowe NJ Ashton RE Koudsi H . Anthralin for psoriasis: Short contact anthralin therapy compared with topical steroid and conventional anthralin. J Am Acad Dermatol 1984; 10:69–72

Schwarz T Gschnait F . Anthralin minute entire skin treatment. A new outpatient therapy for psoriasis. Arch Dermatol 1985; 121:1512–1515

Miller AC . Anthralin cream as short contact therapy for psoriasis. Cutis 1985; 35:578–582

Ramsey B Lawrence CM Bruce JM . The effect of triethanolamine application on anthralin–induced inflammation and therapeutic effect on psoriasis. J Am Acad Dermatol 1990; 23:73–76

Downey DJ Finlay AY . Combined short contact crude coal tar and dithranol therapy for psoriasis. Clin Exp Dermatol 1986; 11:498–501

Muller R Naumann E Detman M . Stability of cignolin (dithranol) in ointments containing tar with and without the addition of salicylic acid. Oxidation to anthron and dithranol dime. Hautarzt 1987; 38:107–111

Weinrich EG . Dermatopharmacology of salicylic acid. Dermatologica 1975; 15:114–116

Huber C Christophers E . “Keratolytic” effects of salicylic acid. Arch Dermatol Res 1977; 257:293–297

Lin AN Nakatsui T . Salicylic acid revisited. Int J Dermatol 1998; 37:335–342

Birmingham BK Greene DS Rhodes CT . Systemic absorption of topical salicylic acid. Int J Dermatol 1979; 18:228–231

Taylor JR Halprin KM . Percutaneous absorption of salicylic acid. Arch Dermatol 1975; 111:740–743

Stolar ME Rossi GV Barr M . The effect of various ointment bases on the percutaneous absorption of salicylates. I. Effect of type of ointment base. J Am Pharmacol Assoc 1960; 49:114–147

Lebwohl M . The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999; 38:16–24

Lebwohl M Tan M Gelfand JM . Clinically significant therapeutic interactions for the practicing dermatologist. Adv Dermatol 1999; 14:1–27

Krochmal L Wang JT Patel B . Topical corticosteroid compounding: Effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol 1989; 21:979–984

Polano MK Ponec M . Dependence of corticosteroid penetration on the vehicle. Arch Dermatol 1976; 112:675–680

Koo J . Mometasone furoate/salicylic acid combination welcomed. Psoriasis Forum 1997; 3:1

Ling MR . Extemporaneous compounding. Dermtol Clin 1998; 16:321–327